Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock
NCT ID: NCT03189355
Last Updated: 2017-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
52 participants
INTERVENTIONAL
2017-01-09
2019-02-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Muscle mass results from a balance between the pathway of proteolysis and that of protein synthesis, depending on many factors, not one of the most important are insulin. The protein PTP1B (Protein Tyrosine Phosphatase 1B), by the dephosphorylation of its numerous substrates, constitutes an endogenous regulator of numerous intracellular signaling pathways, including that of insulin. PTP1B could play a role in the protein synthesis abnormalities observed during sepsis leading clinically to impaired body composition including muscle body mass. Therefore, we propose to study the association between PTP1B and loss of muscle mass in patients in sepsis in resuscitation.
The intestinal barrier plays an essential role in protecting against microbial luminal flora and the phenomenon of bacterial translocation. Zonulin is one of the major regulators of tight junctions, important actors in the intestinal barrier function. The increase in plasma zonulin levels, greater than 0.6 ng / mg, is directly correlated with increased intestinal permeability (16). However, elevation of plasma zonulin has never been evaluated in septic resuscitation patients. This is why we propose the evaluation of the association between plasma zonulin and the loss of muscle mass in these resuscitation patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Muscle Lactate and Lactate to Pyruvate Ratio Clearance in Septic Shock Patients
NCT03700346
Effect of Lipopolysaccharide on Skeletal Muscle Functions
NCT01423968
Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis
NCT00541827
Evolution of Muscle Function, Breathlessness and Quality of Life Following Intra or Extra-Abdominal Sepsis in ICU Patients
NCT06010186
Comparison of Short Peptide and Whole Protein Formula in the Early Enteral Nutrition of Patients With Sepsis
NCT07038057
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients With Septic Shock
Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
Blood sampling
* D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube
* D4 zonulin
Bioelectrical impedance vector analysis
* D1
* D4
Muscular echography
* D1
* D4
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
* D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube
* D4 zonulin
Bioelectrical impedance vector analysis
* D1
* D4
Muscular echography
* D1
* D4
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years old
* Affiliation to a social security system
* Information and consent. If patient cannot give his consent, an emergency consent will be sign by trusted person
* Contraception for woman, of childbearing age
Exclusion Criteria
* Prisoners
* Patient with pacemaker or defibrillator
* patient participating to a clinical trial with the same primary outcome
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Caroline LEMAITRE
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rouen University Hospital
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Caroline LEMAITRE, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016/108/HP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.